Multiple sclerosis is the commonest cause of neurological disability in young adults affecting at least 60 000 people within the United Kingdom alone. It has been the subject of numerous epidemiological surveys reporting widely varying prevalence from 13 tinuing requirement for epidemiological studies, particularly in the heavily populated southern areas of England, with contemporary classifications of disease state and taking into account advances in laboratory investigations; these provide information for health service planning and allow the testing of aetiological hypotheses by comparing the frequency of multiple sclerosis in different populations.
The first epidemiological study of multiple sclerosis in East Anglia, performed in 198812 reported a prevalence of 153/105 for probable disease alone using the Allison and Millar criteria'3 in five rural Suffolk practices, and confirmed East Anglia as a high prevalence area for the disease. As part of an ongoing study of the genetic epidemiology of multiple sclerosis, a prospective register of prevalent and incident cases was established in 1989 
Results
The provisional register contained 563 patients from all sources, of which 324 were derived from departmental notes, 318 from general practitioner notifications, 85 from the Multiple Sclerosis Society, seven from residential facilities for the disabled, and 105 from the Peterborough hospitals database. Fifty eight of the 60 general practitioner practices responded to the request to participate in the study; one practice preferred not to supply information on the grounds of patient confidentiality and one small practice failed to respond to serial requests for information. One hundred (18%) patients on the provisional register had either died, moved away from the area, were duplicate referrals, or it had become clear that an alternative diagnosis had been established, and these were all excluded. After further clinical evaluation based on personal interview or review of existing medical records, the diagnosis could not be confirmed in a further 13 patients; alternative diagnoses included adrenoleucodystrophy (one), functional illness (four), vasculitis (two), cervical myelopathy (one), Parkinson's disease (one), and the remainder had transient symptoms suggestive of neurological disease but an absence of clinical signs (four). Patients were also excluded if they had died before prevalence day or were not resident in the area as defined by the main address at which they were registered with their general practitioner. The final register therefore comprised 449 patients with multiple sclerosis, alive and prevalent within the study area on 1 July 1993. The largest source for ascertainment of prevalent patients was Ireland, which used the Allison and Millar criteria, it became clear that a group equivalent to the possible category was needed. It was first used in the south Glamorgan study in 1985 and is now accepted as referring to those suspected of having demyelinating disease but without signs or paraclinical evidence for more than one lesion. In our population in whom disease course at onset and time to second episode could be established the median time to second relapse was 3-5 years and 95% had a second episode of dysfunction within 10 years. Forty two of 48 patients classified as suspected disease in our study had relapsing disease; of these, 10 (24%) had their single episode of neurological dysfunction more than 10 years previously and so now seem less likely to develop further manifestations of disease that would move them to a firmer classification. In south Glamorgan the suspected category accounted for 60 (14%) of the total number of prevalent patients; in south Cambridgeshire this was 54 (14%) and in Southampton 16 (4%); Sussex, Jersey, and Guernsey studies have not included suspected disease within their overall prevalence figures. The paucity of suspected cases in the Southampton study was noted by the authors who postulated that this may have resulted from the low proportion ascertained from departmental indices or from a regional diagnostic bias. For the present, all patients with suspected disease are included irrespective of the temporal relation to their symptoms, but care should be taken in future that apparent changes in prevalence are not simply the result of an increase in this suspected category, a substantial proportion of whom will not develop definite or probable disease. For this reason, publication of prevalence figures should clearly indicate whether they represent all disease classifications or simply definite and probable, the second being the more robust statistic. Once these points are taken into account, there exists an emerging pattern of stability in disease prevalence in the southern United Kingdom and a simple linear relation between latitude and prevalence within the United Kingdom now seems unlikely.
Because multiple sclerosis is more common in females and young adults, standardisation of the population to take account of differences in age and sex structure has been a popular method of examining differences in prevalence in United Kingdom studies and has universally used the 1961 population of Northern Ireland as standard. The effect has been to eliminate all significant difference in prevalence except those between the southern England studies and Aberdeen where the contemporary rate is the result of serial surveys. Despite widely quoted differences, however, in prevalence between certain ethnic minority groups and Caucasians,2." little attempt has been made either in or outside the United Kingdom to allow for the ethnic mix of the population under study. One exception is the study of multiple sclerosis in north and south New Zealand in 198132 where quoted figures for prevalence exclude the Maori population.
Certainly there is a significant difference in ethnic mix between north and south Cambridgeshire, which accounts in part for the slight difference in prevalence; it would seem reasonable to quote that proportion of the population made up by ethnic minorities to ensure that this makes no significant difference to prevalence.
Other factors that may produce local differences in prevalence include the size of the population; smaller, well defined geographical areas may be expected to deliver a more complete case ascertainment and may explain some of the disproportionate increase in certain island populations. Other factors that introduce artefacts include the location of residential facilities for the disabled, distance from the regional neurological centre, disribution of general practitioners, and the role of serial studies. In Aberdeen, 3 
